Product Description
Mechanisms of Action: AMPA Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02223507 |
NCT02223507 | P1 |
Completed |
Healthy Volunteers |
2000-09-01 |
2019-03-20 |
Treatments |
|
NCT02222961 |
NCT02222961 | P1 |
Completed |
Healthy Volunteers |
2000-06-01 |
2019-03-20 |
Treatments |
|
NCT02222974 |
NCT02222974 | P1 |
Completed |
Healthy Volunteers |
1999-08-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|